High-sensitivity troponin I in persistent atrial fibrillation - relation to NT-proBNP and markers of inflammation and haemostasis
- PMID: 29933716
- DOI: 10.1080/00365513.2018.1481224
High-sensitivity troponin I in persistent atrial fibrillation - relation to NT-proBNP and markers of inflammation and haemostasis
Abstract
Purpose: As cardiac troponins emerge as prognostic markers in atrial fibrillation (AF), it is important to identify mechanisms initiating and perpetuating cardiac troponin release, including its relations to other circulating biomarkers, in AF populations. We studied associations between high-sensitivity troponin I (hs-TnI) and markers representing myocardial wall tension, inflammation and haemostasis in persistent AF.
Methods: In a double blind, placebo-controlled study, 171 patients referred for electrical cardioversion for persistent AF were randomised to receive candesartan or placebo for 3-6 weeks before and 6 months after cardioversion. Associations between baseline levels of hs-TnI and other biomarkers were investigated by bivariate non-parametric correlations (Spearman's correlation coefficient denoted rs).
Results: Baseline levels of hs-TnI correlated significantly, although weakly, with interleukin-6 (rs = 0.260, p = .003), N-terminal pro-B-type natriuretic peptide (rs = 0.251, p = .004), tissue-plasminogen activator antigen (rs = 0.233, p = .008), D-dimer (rs = 0.220, p = .013), E-selectin (rs = 0.207, p = .019), high-sensitivity C-reactive protein (rs = 0.202, p = .022) and vascular cell adhesion molecule-1 (rs = 0.189, p = .032).
Conclusions: Hs-TnI correlated weakly with biomarkers representing myocardial wall tension, inflammation and haemostasis in persistent AF. The lack of any strong correlation between hs-TnI and the investigated biomarkers is in concert with the idea that hs-TnI release is an independent process parallel to other pathophysiological mechanisms associated with AF.
Keywords: Atrial fibrillation; CHA2DS2-VASc score; biomarkers; cardiac troponins; cardiology; endothelial activation; haemostasis; high-sensitivity troponin I; inflammation.
Similar articles
-
High-Sensitivity Troponin I and Rhythm Outcome after Electrical Cardioversion for Persistent Atrial Fibrillation.Cardiology. 2016;133(4):233-8. doi: 10.1159/000442249. Epub 2015 Dec 24. Cardiology. 2016. PMID: 26697854 Clinical Trial.
-
Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation.Am J Cardiol. 2007 Jun 1;99(11):1544-8. doi: 10.1016/j.amjcard.2007.01.030. Epub 2007 Apr 16. Am J Cardiol. 2007. PMID: 17531578 Clinical Trial.
-
Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion.Int J Cardiol. 2009 Jan 9;131(2):234-9. doi: 10.1016/j.ijcard.2007.10.028. Epub 2008 Jan 16. Int J Cardiol. 2009. PMID: 18201783 Clinical Trial.
-
Biomarkers in atrial fibrillation: a clinical review.Eur Heart J. 2013 May;34(20):1475-80. doi: 10.1093/eurheartj/eht024. Epub 2013 Feb 5. Eur Heart J. 2013. PMID: 23386711 Review.
-
Clinical Applications of Biomarkers in Atrial Fibrillation.Am J Med. 2017 Dec;130(12):1351-1357. doi: 10.1016/j.amjmed.2017.08.003. Epub 2017 Aug 16. Am J Med. 2017. PMID: 28822701 Review.
Cited by
-
Effect of Endothelial Adhesion Molecules on Atrial Fibrillation: A Systematic Review and Meta-analysis.Heart Int. 2022 Aug 31;16(2):75-84. doi: 10.17925/HI.2022.16.2.75. eCollection 2022. Heart Int. 2022. PMID: 36741104 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials